Open AI's GPT-5 Launch Is Just Days Away, Claims Report
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Powerful System
According to a report in The Verge, OpenAI's chief executive Sam Altman, below, plans to launch the model early next month.
The model, which is understood to combine OpenAI's o-series and GPT-series into a single, powerful system, was expected to be launched this summer. It is understood that the delay was due to the need for additional testing.
The new model will reportedly be 'positioned as an AI system that incorporates distinct models and can perform different functions as opposed to just a single AI model.'
The Microsoft (MSFT) -backed startup did not comment, although as reported by TipRanks earlier this year the company is keen to simplify its offerings.
Altman has said that this isn't just about making an AI that can handle more tasks; it's about creating one that thinks more deeply before it responds. This means we can expect future versions to not only be more efficient but also to offer richer, more thoughtful interactions.
Reasoning Skills
In addition, GPT-5 is more than just a simple update. It brings in the reasoning skills from the o-series, particularly the o3 model, which means it's going to be smarter and more aware of the context it's working in. This should help cut down on errors and boost performance.
The essence of the system is that it should be a smarter version of what we have seen before and make it easier and more useful for users from employees to students or ordinary folk.
In fact, Altman wants to make a free copy of GPT-5 available to everybody. 'I am very interested in what it means to give everybody on Earth a free copy of GPT-5, running for them all the time,' he said.
But let's not get too carried away. The Verge report did have some caveats.
'While GPT-5 looks likely to debut in early August, OpenAI's planned release dates often shift to respond to development challenges, server capacity issues, or even rival AI model announcements and leaks,' the report said.
TipRanks comparison tool.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
32 minutes ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Yahoo
an hour ago
- Yahoo
Is Visa (V) a Smart Buy and Hold Stock in the Tech-Driven Market?
Visa Inc. (NYSE:V) is included among the 10 Best Dividend Stocks to Buy and Hold Forever. siam sompunya The company is embracing AI to stay ahead, launching its Intelligent Commerce platform that uses AI agents for shopping, digital credentials, and personalized payment insights. It's working with top tech firms like OpenAI and Microsoft, and has upgraded its platform with AI features. Visa also acquired AI-based fraud detection firm Featurespace to boost security. On the financial side, Visa Inc. (NYSE:V) is a strong dividend stock with 17 years of consecutive increases and a low 18.5% payout ratio. As a payment processor, it profits from card usage without lending risk, making it a reliable stock in any economy. Over the past decade, the company has delivered an impressive annualized dividend growth rate of 17%. While recent increases have been slightly more modest, the one-, three-, and five-year growth rates all remain above 10%, making Visa a strong pick for dividend growth investors. On July 29, Visa Inc. (NYSE:V) declared a quarterly dividend of $0.59 per share, which fell in line with its previous dividend. As of July 31, the stock has a dividend yield of 0.68%. While we acknowledge the potential of V as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
IBM's Data Breach Report Warns that AI Tools Are Growing Hacker Targets
Tech giant IBM (IBM) recently released its 2025 Cost of a Data Breach Report, which showed that companies are adopting artificial intelligence far faster than they are securing it. For the first time, the report looked at breaches that involved AI systems and found that 13% of organizations experienced an AI-related breach, while another 8% did not even know if they had been compromised. Among those affected, 97% lacked basic security controls for AI systems, which resulted in 60% of incidents exposing data and 31% disrupting operations. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One major issue identified in the report is 'shadow AI,' or unauthorized AI tools that are being used within organizations. These tools were linked to one in five breaches and typically cost $670,000 more to fix than breaches that did not involve shadow AI. They also exposed more sensitive data, such as personal information and intellectual property, compared to the global average. Furthermore, attackers themselves are now using AI in their methods, with 16% of breaches involving tactics like AI-driven phishing and deepfake impersonation. Despite these rising threats, 63% of breached companies have no formal AI governance policies, and even among those that do, only 34% regularly audit for unsanctioned AI use. As a result, the financial impact of breaches is significant. Globally, the average cost of a breach dropped slightly to $4.44 million, but U.S. breaches reached a record $10.22 million. Healthcare breaches continue to be the most expensive, averaging $7.42 million, and take the longest to contain. Interestingly, though, organizations that use AI and automation in their security operations saved an average of $1.9 million in breach costs and shortened the time to resolve breaches by 80 days, which shows that AI can be a powerful defense when properly managed. Is IBM a Buy, Sell, or Hold? Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on seven Buys, four Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $297.33 per share implies 18.9% upside potential.
